Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Summary

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.

Conditions

• Relapsed Pediatric Solid Tumor
• Refractory Pediatric Solid Tumor
• Relapsed Pediatric AML
• Refractory Pediatric AML

Interventions

PROCEDURE

CancerSCAN™

Targeted deep sequencing

DRUG

Ifosfamide

DRUG

Carboplatin

DRUG

Etoposide

DRUG

Fludarabine

DRUG

Cytarabine

DRUG

Pazopanib

DRUG

Sorafenib

DRUG

Axitinib

DRUG

Crizotinib

DRUG

Dasatinib

DRUG

Erlotinib

DRUG

Everolimus

DRUG

Imatinib

DRUG

Ruxolitinib

DRUG

Vandetanib

DRUG

Vemurafenib

DRUG

Trastuzumab

Sponsors & Collaborators

• Ministry of Health, Republic of Korea

  collaborator OTHER_GOV

• Samsung Medical Center

  lead OTHER

Principal Investigators

• Ki Woong Sung, MD, PhD · Samsung Medical Center

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Max Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-12-31

Primary Completion

2021-12-31

Completion

2023-12-31

Countries

• South Korea

Study Locations